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background:  Oral anticoagulation (OAC) for stroke prevention is an important treatment in managing patients with atrial fibrillation (AF). 
Presently, little is known regarding the factors influencing the use of new OAC agents (NOAC) vs. vitamin-K antagonists (VKA) in clinical practice. We 
sought to identify factors associated with NOAC vs. VKA use in a contemporary, national, real-world observational registry.
methods:  From December 2012 to July 2013, we conducted a cross-sectional analysis of 850 consecutive AF patients from 101 practices in 10 
Canadian provinces. Seven hundred and five patients (83%) were treated with any OAC. Multivariable logistic regression was performed to identify 
factors associated with NOAC vs. VKA use.
results:  Three hundred thirty-six (47.7%) patients were treated with NOAC and 369 (52.3%) patients were treated with VKA. On multivariable 
analysis, factors associated with NOAC use (vs. VKA) include: improved side effect profile, physician perceived efficacy, and NSAID use. Factors 
associated with VKA use (vs. NOAC) include: non-paroxysmal AF, history of coronary artery disease, and cost. (Figure)
conclusions:  In this contemporary and national registry of AF patients, we identified several clinical and subjective patient/physician preference 
factors associated with NOAC vs. VKA use. Notably, patient-centered factors such as perceived side effect profile and cost appear highly relevant 
when selecting NOAC vs. VKA in contemporary AF practice.
 
